|
1
|
World Health Organization: COVID-19:
Vulnerable and high-risk groups.
|
|
2
|
CDC. Underlying conditions and the higher
risk for severe COVID-19.
|
|
3
|
Polack FP, Thomas SJ, Kitchin N, Absalon
J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED,
Zerbini C, et al: Safety and efficacy of the BNT162b2 mRNA Covid-19
vaccine. N Engl J Med. 383:2603–2615. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Thomas SJ, Moreira ED Jr, Kitchin N,
Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack
FP, Zerbini C, et al: Safety and efficacy of the BNT162b2 mRNA
Covid-19 vaccine through 6 months. N Engl J Med. 385:1761–1773.
2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Moreira ED Jr, Kitchin N, Xu X, Dychter
SS, Lockhart S, Gurtman A, Perez JL, Zerbini C, Dever ME, Jennings
TW, et al: Safety and efficacy of a third dose of BNT162b2 Covid-19
vaccine. N Engl J Med. 386:1910–1921. 2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Aktaş G: A comprehensive review on
rational and effective treatment strategies against an invisible
enemy; SARS Cov-2 infection. Exp Biomed Res. 3:293–311. 2020.
|
|
7
|
Wu Z and McGoogan JM: Characteristics of
and important lessons from the coronavirus disease 2019 (COVID-19)
outbreak in china: summary of a report of 72 314 cases from the
Chinese center for disease control and prevention. JAMA.
323:1239–1242. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Aktas G, Balci B, Yilmaz S, Bardak H,
Duman TT and Civil C: Characteristics of Covid-19 infection with
the original SARS-Cov-2 virus and other variants: A comparative
review. J Bionic Mem. 2:96–112. 2022.
|
|
9
|
Aktas G: Hematological predictors of novel
coronavirus infection. Rev Assoc Med Bras (1992). 67 (Suppl
1):S1–S2. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Atak BM, Kahveci G, Bilgin S, Kurtkulagi
O, Taslamacioglu Duman T, Demirkol ME and Aktas G: Haemoglobin and
red cell distribution width levels in internal medicine patients
indicate recurrent hospital admission during COVID-19. Fam Med Prim
Care Rev. 24:32–36. 2022.
|
|
11
|
Atak BM, Bilgin S, Kurtkulagi O, Kahveci
G, Taslamacioglu Duman T, Sagdic T and Aktas G: Frailty in diabetic
subjects during Covid-19 and its association with HbA1c, mean
platelet volume and monocyte/lymphocyte ratio. Clin Diabetol.
11:119–126. 2022.
|
|
12
|
Ostrowski SR, Søgaard OS, Tolstrup M,
Stærke NB, Lundgren J, Østergaard L and Hvas AM: Inflammation and
platelet activation after COVID-19 vaccines-possible mechanisms
behind vaccine-induced immune thrombocytopenia and thrombosis.
Front Immunol. 12(779453)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kumar G, Adams A, Hererra M, Rojas ER,
Singh V, Sakhuja A, Meersman M, Dalton D, Kethireddy S, Nanchal R
and Guddati AK: Predictors and outcomes of healthcare-associated
infections in COVID-19 patients. Int J Infect Dis. 104:287–292.
2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Pilishvili T, Gierke R, Fleming-Dutra KE,
Farrar JL, Mohr NM, Talan DA, Krishnadasan A, Harland KK, Smithline
HA, Hou PC, et al: Effectiveness of mRNA Covid-19 vaccine among
U.S. health care personnel. N Engl J Med. 385(e90)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Benenson S, Oster Y, Cohen MJ and Nir-Paz
R: BNT162b2 mRNA Covid-19 vaccine effectiveness among health care
workers. N Engl J Med. 384:1775–1777. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Paris C, Perrin S, Hamonic S, Bourget B,
Roué C, Brassard O, Tadié E, Gicquel V, Bénézit F, Thibault V, et
al: Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19
vaccines against COVID-19 in healthcare workers: An observational
study using surveillance data. Clin Microbiol Infect.
27:1699.e5–e8. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hall VJ, Foulkes S, Saei A, Andrews N,
Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A, et
al: COVID-19 vaccine coverage in health-care workers in England and
effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A
prospective, multicentre, cohort study. Lancet. 397:1725–1735.
2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Feikin DR, Higdon MM, Abu-Raddad LJ,
Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O'Brien KL,
Smith PG, et al: Duration of effectiveness of vaccines against
SARS-CoV-2 infection and COVID-19 disease: Results of a systematic
review and meta-regression. Lancet. 399:924–944. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bobrovitz N, Ware H, Ma X, Li Z, Hosseini
R, Cao C, Selemon A, Whelan M, Premji Z, Issa H, et al: Protective
effectiveness of previous SARS-CoV-2 infection and hybrid immunity
against the omicron variant and severe disease: A systematic review
and meta-regression. Lancet Infect Dis. 23:556–567. 2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Levin EG, Lustig Y, Cohen C, Fluss R,
Indenbaum V, Amit S, Doolman R, Asraf K, Mendelson E, Ziv A, et al:
Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6
months. N Engl J Med. 385(e84)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Palacka P, Pol'anová M, Svobodová A,
Žigmond J, Zanchetta K, Gombárová V, Vulganová M, Slopovský J,
Obertová J, Drgoňa Ľ, et al: Effectiveness, adverse events, and
immune response following double vaccination with BNT162b2 in staff
at the national comprehensive cancer center (NCCC). Vaccines
(Basel). 10(558)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Siemens Healthineers: SARS-CoV-2 IgG
(sCOVG) assay for the detection of IgG antibodies to SARS-CoV-2.
https://www.fda.gov/media/146931/download. Accessed
August 26, 2023.
|
|
23
|
National Council for the Social Studies
(NCSS): NCSS Statistical Software. NCSS, LLC, Kaysville, UT, 2024.
https://www.ncss.com/.
|
|
24
|
Thompson CG, Kim RS, Aloe AM and Becker
BJ: Extracting the variance inflation factor and other
multicollinearity diagnostics from typical regression results.
Basic Appl Soc Psychol. 39:81–90. 2017.
|
|
25
|
Monitorovacia správa cirkulujúcich
variantov vírusu SARS-CoV-2 v Slovenskej republike zachytených v
systéme NarCoS-Národné Covid-19 Sekvenovanie.
|
|
26
|
Kiss Z, Wittmann I, Polivka L, Surján G,
Surján O, Barcza Z, Molnár GA, Nagy D, Müller V, Bogos K, et al:
Nationwide effectiveness of first and second SARS-CoV2 booster
vaccines during the delta and omicron pandemic waves in Hungary
(HUN-VE 2 study). Front Immunol. 13(905585)2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Szekanecz Z, Vokó Z, Surján O, Rákóczi É,
Szamosi S, Szűcs G, Szekanecz É, Müller C and Kiss Z: Effectiveness
and waning of protection with the BNT162b2 vaccine against the
SARS-CoV-2 delta variant in immunocompromised individuals. Front
Immunol. 14(1247129)2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Berec L, Šmíd M, Přibylová L, Májek O,
Pavlík T, Jarkovský J, Zajíček M, Weiner J, Barusová T and Trnka J:
Protection provided by vaccination, booster doses and previous
infection against covid-19 infection, hospitalisation or death over
time in Czechia. PLoS One. 17(e0270801)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Oster Y, Benenson S, Nir-Paz R, Buda I and
Cohen MJ: The effect of a third BNT162b2 vaccine on breakthrough
infections in health care workers: A cohort analysis. Clin
Microbiol Infect. 28:735.e1–e3. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Klein SL and Flanagan KL: Sex differences
in immune responses. Nat Rev Immunol. 16:626–638. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tadount F, Doyon-Plourde P, Rafferty E,
MacDonald S, Sadarangani M and Quach C: Is there a difference in
the immune response, efficacy, effectiveness and safety of seasonal
influenza vaccine in males and females?-A systematic review.
Vaccine. 38:444–459. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Green MS, Peer V, Magid A, Hagani N, Anis
E and Nitzan D: Gender differences in adverse events following the
Pfizer-BioNTech COVID-19 vaccine. Vaccines (Basel).
10(233)2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wei J, Stoesser N, Matthews PC, Ayoubkhani
D, Studley R, Bell I, Bell JI, Newton JN, Farrar J, Diamond I, et
al: Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from
the general population of the United Kingdom. Nat Microbiol.
6:1140–1149. 2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Amodio E, Capra G, Casuccio A, De Grazia
S, Genovese D, Pizzo S, Calamusa G, Ferraro D, Giammanco GM, Vitale
F and Bonura F: Antibodies responses to SARS-CoV-2 in a large
cohort of vaccinated subjects and seropositive patients. Vaccines
(Basel). 9(714)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Đaković Rode O, Bodulić K, Zember S,
Cetinić Balent N, Novokmet A, Čulo M, Rašić Ž, Mikulić R and
Markotić A: Decline of anti-SARS-CoV-2 IgG antibody levels 6 months
after complete BNT162b2 vaccination in healthcare workers to levels
observed following the first vaccine dose. Vaccines (Basel).
10(153)2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Papaioannidou P, Skoumpa K, Bostanitis C,
Michailidou M, Stergiopoulou T, Bostanitis I and Tsalidou M: Age,
sex and BMI relations with anti-SARS-CoV-2-Spike IgG antibodies
after BNT162b2 COVID-19 vaccine in health care workers in Northern
Greece. Microorganisms. 11(1279)2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Braun E, Horowitz NA, Leiba R, Weissman A,
Mekel M, Shachor-Meyouhas Y, Hussein K, Halberthal M, Azzam ZS and
Berger G: Association between IgG antibody levels and adverse
events after first and second Bnt162b2 mRNA vaccine doses. Clin
Microbiol Infect. 28:1644–1648. 2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ailsworth SM, Keshavarz B, Richards NE,
Workman LJ, Murphy DD, Nelson MR, Platts-Mills TAE and Wilson JM:
Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster
vaccination and comparison of BNT162b2 with mRNA-1273. Ann Allergy
Asthma Immunol. 130:67–73. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wolszczak-Biedrzycka B, Bieńkowska A and
Dorf J: Assessment of post-vaccination antibody response eight
months after the administration of BNT1622b2 vaccine to healthcare
workers with particular emphasis on the impact of previous COVID-19
infection. Vaccines (Basel). 9(1508)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wolszczak-Biedrzycka B, Bieńkowska A,
Zaborowska JE, Smolińska-Fijołek E, Biedrzycki G and Dorf J:
Anti-SARS-CoV-2S antibody levels in healthcare workers 10 months
after the administration of two BNT162b2 vaccine doses in view of
demographic characteristic and previous COVID-19 infection.
Vaccines (Basel). 10(741)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wolszczak Biedrzycka B, Bieńkowska A,
Smolińska-Fijołek E, Biedrzycki G and Dorf J: The influence of two
priming doses of different anti-COVID-19 vaccines on the production
of anti-SARS-CoV-2 antibodies after the administration of the
Pfizer/BioNTech booster. Infect Drug Resist. 15:7811–7821.
2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wolszczak-Biedrzycka B, Bieńkowska A,
Cieślikiewicz B, Smolińska-Fijołek E, Biedrzycki G and Dorf J: The
effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2
spike antibody levels in healthcare workers with and without
COVID-19 infection. Ann Med. 55:722–732. 2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Sumbalova Z, Kucharska J, Palacka P,
Rausova Z, Langsjoen PH, Langsjoen AM and Gvozdjakova A: Platelet
mitochondrial function and endogenous coenzyme Q10 levels are
reduced in patients after COVID-19. Bratisl Lek Listy. 123:9–15.
2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Gvozdjáková A, Kucharská J, Rausová Z,
Lopéz-Lluch G, Navas P, Palacka P, Bartolčičová B and Sumbalová Z:
Effect of vaccination on platelet mitochondrial bioenergy function
of patients with post-acute COVID-19. Viruses.
15(1085)2023.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Notarte KI, Ver AT, Velasco JV, Pastrana
A, Catahay JA, Salvagno GL, Yap EPH, Martinez-Sobrido L, B
Torrelles J, Lippi G and Henry BM: Effects of age, sex, serostatus,
and underlying comorbidities on humoral response post-SARS-CoV-2
Pfizer-BioNTech mRNA vaccination: A systematic review. Crit Rev
Clin Lab Sci. 59:373–390. 2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Francisco V, Pino J, Campos-Cabaleiro V,
Ruiz-Fernández C, Mera A, Gonzalez-Gay MA, Gómez R and Gualillo O:
Obesity, fat mass and immune system: Role for leptin. Front
Physiol. 9(640)2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Petrone D, Mateo-Urdiales A, Sacco C,
Riccardo F, Bella A, Ambrosio L, Lo Presti A, Di Martino A,
Ceccarelli E, Del Manso M, et al: Reduction of the risk of severe
COVID-19 due to omicron compared to delta variant in Italy
(November 2021-February 2022). Int J Infect Dis. 129:135–141.
2023.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Sarker R, Roknuzzaman ASM, Nazmunnahar
Hossain MJ and Islam MR: Benefits and probable ill effects of WHO's
declaration of end of COVID-19 pandemic: A way back to
pandemic-free normal life. Ann Med Surg (Lond). 85:3199–3201.
2023.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Roknuzzaman A, Sarker R, Nazmunnahar
Shahriar M, Mosharrafa RA and Islam MR: The WHO has declared
COVID-19 is no longer a pandemic-level threat: A perspective
evaluating potential public health impacts. Clin Pathol.
17(2632010X241228053)2024.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Koolaparambil Mukesh R, Yinda CK, Munster
VJ and van Doremalen N: Beyond COVID-19: The promise of
next-generation coronavirus vaccines. NPJ Viruses.
2(39)2024.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Singh C, Verma S, Reddy P, Diamond MS,
Curiel DT, Patel C, Jain MK, Redkar SV, Bhate AS, Gundappa V, et
al: Phase III pivotal comparative clinical trial of intranasal
(iNCOVACC) and intramuscular COVID 19 vaccine
(Covaxin®). NPJ Vaccines. 8(125)2023.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Vishwanath S, Carnell GW, Ferrari M,
Asbach B, Billmeier M, George C, Sans MS, Nadesalingam A, Huang CQ,
Paloniemi M, et al: A computationally designed antigen eliciting
broad humoral responses against SARS-CoV-2 and related
sarbecoviruses. Nat Biomed Eng. 9:153–166. 2025.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Carreño JM, Raskin A, Singh G, Tcheou J,
Kawabata H, Gleason C, Srivastava K, Vigdorovich V, Dambrauskas N,
Gupta SL, et al: An inactivated NDV-HXP-S COVID-19 vaccine elicits
a higher proportion of neutralizing antibodies in humans than mRNA
vaccination. Sci Transl Med. 15(eabo2847)2023.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Xu K, Lei W, Kang B, Yang H, Wang Y, Lu Y,
Lv L, Sun Y, Zhang J, Wang X, et al: A novel mRNA vaccine, SYS6006,
against SARS-CoV-2. Front Immunol. 13(1051576)2023.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Ao D, He X, Liu J and Xu L: Strategies for
the development and approval of COVID-19 vaccines and therapeutics
in the post-pandemic period. Signal Transduct Target Ther.
8(466)2023.PubMed/NCBI View Article : Google Scholar
|
